Life Extension Magazine November 2008
Regenerative Medicine Breakthroughs
Will BioTime Reset the Clock of Aging?
By Julius Goepp, MD
iPS: From Vision to Reality
Dr. West’s exciting work at publicly traded BioTime, Inc. is aimed at making that vision a reality on the fast track. West’s team is working on a “reprogramming matrix.” BioTime recently licensed patents Dr. West had filed years before the publication of papers on human iPS cells that cover the use of the iPS genes in turning back the clock of human aging. “The goal is to use this material to permanently re-engineer old cells (say from a 100-year-old person), and bring them back to cells indistinguishable from those they were born with 100 years earlier.
“We’re faced with a ‘tsunami’ of aging,’” West says, “and with the age wave of the baby boom generation, the timing is right for us as a nation to utilize these technologies to offer lower-cost therapies for crippling diseases like arthritis, for example. If we can rebuild the cartilage in your joints so you can walk to the store, the cost savings alone to this country would be just enormous. Many people have no idea that this emerging field of regenerative medicine was born of a desire to find a means to regenerate tissue function in the aged human and directly address this enormous human need.
“Now that we can turn back the arrow of time on human cells, the next question is how to learn how to make the cell types we need in a purified form and industrial scale for a host of age-related diseases. The good news here is that we’ve made some remarkable progress already.”
The challenge Dr. West refers to is that scientists still don’t understand just how stem cells “figure out” what kind of tissue they are destined to turn into. During natural embryonic development, there are specific genetic codes that seem to help cells “recognize” their environment, so that a cell developing at a location past the elbow joint turns into part of a wrist, a hand, or a finger—and never into an upper arm or a shoulder.25-27 “In some primitive animals,” West points out, “an arm amputated above the elbow regenerates with a normal elbow and everything beyond it—but if the amputation is below the elbow, the limb grows back without producing a second elbow.”
So today’s stem cell researchers must “decode” the cells’ intricate and complex position-finding mechanism—a daunting task considering the thousands of cell types and subtypes in the body, which not only have to form properly, but then must work together correctly. Or is that arduous decoding actually necessary? According to West, absolutely not.
Using a bold new approach, West’s lab simply exposes stem cells to a “shotgun” mix of conditions, and then uses modern genetic techniques to figure out what they’ve produced. “Instead of looking up at the apple tree and saying, ‘we want to pick that particular apple right there,’ West says, “we just lay out a tarp on the ground and shake the tree. It’s a random approach, but it is turning out to be very powerful—we produced 140 different cell types in just our first experiment alone.” Each of those 140 types is known as an embryonic progenitor cell—more advanced than a stem cell, but still capable of developing into many cells of a particular tissue type—say cells in the musculoskeletal system, or blood cells, or even nervous system tissue.28 These cells may have the capacity to “recognize” their environment when injected into injured or aged tissue, and proceed to develop into appropriate cell types and even organize themselves into functioning tissue based on the environment in which they find themselves.
“The bottom line,” Dr. West says, “is that for the first time, medicine has an all-powerful stem cell to make everything in the human body, and young cells of any kind can be generated that are genetic matches to the patient who needs them. The hope—I would even say the anticipation—is that we’ll be able to fulfill the vision of regenerative medicine, which is to make cells for an old person just like those they were born from decades earlier. They can be used to regenerate at least some aspects of the human body’s function, whether it be the heart or the hair cell of the inner ear to restore hearing, and so on.”
The Bright Future of Stem Cell Therapy
In wrapping up, we ask Dr. West to speculate cautiously which of the major age-related diseases might be addressed with the new technology within the lifetime of people reading this article.
“First I think it’s important to understand that we’re very early in the dawn of this phase of medicine. The Bush administration’s highly ill-advised restrictions on funding in this area continue to hamper progress, though California has stepped up to the plate with three billion dollars to advance the field. But with those caveats, I’m still terribly excited about how we can potentially affect some of the largest aspects of aging.”
“There’s an old adage in gerontology,” West continues, “that ‘you’re only as old as your arteries.” In fact, children afflicted with catastrophic premature aging diseases such as progeria and Werner’s syndrome have the identical, short-telomere-induced cardiovascular changes as people literally 10 times their age.29 “We can actually see vascular endothelial cells getting old by measuring their telomeres—the cells “know” in a sense that there’s something terribly wrong, and then send out signals that arrest normal blood flow, accelerate clotting, and produce inflammatory signals that cause immune cells to invade the vessel wall—that’s what produces cardiovascular disease.”
“Well, could we fix that? At my previous company, we showed that it is possible to make young circulating precursors that can become either blood vessel cells or actual blood cells. We could actually label those cells and watch them traffic through the blood and see them land in damaged vessels and patch the damage. So we believe that if you could infuse the aged human with these cells, we could not only give older people a younger immune system, but we could potentially repair their vasculature as well.” In fact, human studies now bear out these cells’ potential for stimulating vessel growth in ischemic tissues.30,31
So is the implication that one can not only stop further aging with this technology, but perhaps actually reverse some existing changes? “There are animal data to suggest that,” Dr. West responds. In fact, a quick search of the medical literature for 2008 alone reveals the following astonishing discoveries:
iPS cells from patients with the crippling paralytic disease, amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), can be directed to develop into functioning motor nerve cells;32 injection of stem cells into humans has already been shown to be safe and effective at slowing ALS disease progression.33
Laboratory and animal studies have shown that musculoskeletal stem cells can be directed to develop into functional bone and cartilage cells with physical characteristics similar to young healthy bones and joints.34-37
Neural-derived stem cells have improved status of mice with Huntington’s disease, promoted recovery in rats with ischemic stroke, and are being explored as potential therapy for patients with brain tumors.38-40
“We are always accused of hyping all this,” Dr. West says wryly as we end our conversation. “I believe that with time, people will begin to understand the basis of our excitement. The problem is that so many people still believe that aging is inevitable—what they don’t understand is the immortality of the species. I know this defies common wisdom, but common wisdom is perhaps wrong: the reality is that we’re born from cells that have been proliferating since the dawn of life on Earth. That’s just the way it is.”
“As scientists, we’ve got this duty to find ways to clarify truth and dispel myth. We have to explain that aside from the innumerable circus shows, snake oil salesmen, and all that, there’s really serious gerontology at work. Molecular biology today is able to do experiments a thousand times faster and better than it could even 10 years ago, and it’s leading to some really dramatic breakthroughs. Our tools are just so powerful these days. I conceive of the day when we can engineer embryonic stem cells at a molecular level and create new kinds of cells that never existed even in nature.”
Dr. West readily acknowledges that it’s impossible to tell just how far this technology can take us. But with more than 6,000 studies on stem cells published in 2008 alone, it’s clear we are privileged witnesses to a genuine scientific revolution. Will BioTime succeed in reversing the aging of human cells? Must we continue to succumb to aging-related disease and death? Or can we harness the power of our undying cell lineages to achieve a taste of immortality? Only time will tell.
In the meantime, the Life Extension Foundation continues to contribute funding to Dr. West’s pioneering research.
Dr. West is the Chief Executive Officer of BioTime, Inc. and Embryome Sciences, Inc. of Emeryville, California and Adjunct Professor of Bioengineering at the University of California, Berkeley. You can contact Dr. West at firstname.lastname@example.org.
If you have any questions on the scientific content of this article, please call a Life Extension Health Advisor at 1-800-226-2370.
1. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008 Aug 6.
2. Olovnikov AM. Telomeres, telomerase, and aging: origin of the theory. Exp Gerontol. 1996 Jul;31(4):443-8.
3. Olovnikov AM. Aging is a result of a shortening of the “differotene” in the telomere due to end under-replication and under-repair of DNA. Izv Akad Nauk SSSR Biol. 1992 Jul;(4):641-3.
4. Olovnikov AM. Hypothesis: life span is regulated by chronomere DNA of the hypothalamus. J Alzheimers Dis. 2007 May;11(2):241-52.
5. West M. The Immortal Cell. New York: Doubleday; 2003.
6. Farzaneh-Far R, Cawthon RM, Na B, et al. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: data from the Heart and Soul Study. Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1379-84.
7. Han J, Qureshi AA, Prescott J, et al. A Prospective Study of Telomere Length and the Risk of Skin Cancer. J Invest Dermatol. 2008 Jul 31.
8. Huzen J, van Veldhuisen DJ, van Gilst WH, van der Harst P. Telomeres and biological ageing in cardiovascular disease. Ned Tijdschr Geneeskd. 2008 May 31;152(22):1265-70.
9. Kimura M, Hjelmborg JV, Gardner JP, et al. Telomere length and mortality: a study of leukocytes in elderly Danish twins. Am J Epidemiol. 2008 Apr 1;167(7):799-806.
10. Richards JB, Valdes AM, Gardner JP, et al. Homocysteine levels and leukocyte telomere length. Atherosclerosis. 2008 Feb 14.
11. Yu WY, Chang HW, Lin CH, Cho CL. Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J Psychiatry Neurosci. 2008 May;33(3):244-7.
12. Zhang J, Kong Q, Zhang Z, et al. Telomere dysfunction of lymphocytes in patients with Alzheimer disease. Cogn Behav Neurol. 2003 Sep;16(3):170-6.
13. Schuldt AJ, Rosen MR, Gaudette GR, Cohen IS. Repairing damaged myocardium: evaluating cells used for cardiac regeneration. Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):59-72.
14. Shiels PG, Kind AJ, Campbell KH, et al. Analysis of telomere lengths in cloned sheep. Nature. 1999 May 27;399(6734):316-7.
15. Lanza RP, Cibelli JB, Blackwell C, et al. Extension of cell life-span and telomere length in animals cloned from senescent somatic cells. Science. 2000 Apr 28;288(5466):665-9.
16. Doerflinger RM. The problem of deception in embryonic stem cell research. Cell Prolif. 2008 Feb;41 Suppl 165-70.
17. Skene L. Human cloning and stem cell research: engaging in the political process. (Legislation review: prohibition of Human Cloning Act 2002 and the research involving Human Embryos Act). Med Law. 2008 Mar;27(1):119-30.
18. Saunders R, Savulescu J. Research ethics and lessons from Hwanggate: what can we learn from the Korean cloning fraud? J Med Ethics. 2008 Mar;34(3):214-21.
19. Rusnak AJ, Chudley AE. Stem cell research: cloning, therapy and scientific fraud. Clin Genet. 2006 Oct;70(4):302-5.
20. Disgraced Korean cloning scientist indicted. NY Times (Print). 2006;A12.
21. Wohn DY, Normile D. Korean cloning scandal. Prosecutors allege elaborate deception and missing funds. Science. 2006 May 19;312(5776):980-1.
22. Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008 Jul 29;118(5):498-506.
23. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of human-induced pluripotent stem cells. Nat Protoc. 2008;3(7):1180-6.
24. Zhao R, Daley GQ. From fibroblasts to iPS cells: Induced pluripotency by defined factors. J Cell Biochem. 2008 Jul 30.
25. Degnan BM, Degnan SM, Giusti A, Morse DE. A hox/hom homeobox gene in sponges. Gene. 1995 Apr 3;155(2):175-7.
26. Thomas BL, Tucker AS, Ferguson C, et al. Molecular control of odontogenic patterning: positional dependent initiation and morphogenesis. Eur J Oral Sci. 1998 Jan;106 Suppl 1:44-7.
27. Yin Z, Frasch M. Regulation and function of tinman during dorsal mesoderm induction and heart specification in Drosophila. Dev Genet. 1998;22(3):187-200.
28. West MD, Sargent RG, Long J, et al. The ACTCellerate initiative: large-scale combinatorial cloning of novel human embryonic stem cell derivatives. Regen Med. 2008 May;3(3):287-308.
29. Erusalimsky JD, Kurz DJ. Endothelial cell senescence. Handb Exp Pharmacol. 2006;(176 Pt 2):213-48.
30. Cogle CR, Madlambayan GJ, Hubsher G, et al. Marrow cell therapies for cardiovascular diseases. Exp Hematol. 2008 Jun;36(6):687-94.
31. Ribatti D, Nico B, Crivellato E, Vacca A. Endothelial progenitor cells in health and disease. Histol Histopathol. 2005 Oct;20(4):1351-8.
32. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008 Aug 29;321(5893):1218-21.
33. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in Amyotrophic Lateral Sclerosis. J Neurol Sci. 2008 Feb 15;265(1-2):78-83.
34. Ando W, Tateishi K, Katakai D, et al. In Vitro Generation of a Scaffold-Free Tissue-Engineered Construct (TEC) Derived from Human Synovial Mesenchymal Stem Cells: Biological and Mechanical Properties, and Further Chondrogenic Potential. Tissue Eng Part A. 2008 Jul 17.
35. Chang CH, Lin HY, Fang HW, et al. Chondrogenesis from immortalized human mesenchymal stem cells: comparison between collagen gel and pellet culture methods. Artif Organs. 2008 Jul;32(7):561-6.
36. Pei M, He F, Vunjak-Novakovic G. Synovium-derived stem cell-based chondrogenesis. Differentiation. 2008 Jul 2.
37. Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE. 2008;3(7):e2615.
38. Yang CR, Yu RK. Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington’s disease. J Neurosci Res. 2008 Aug 5.
39. Yip S, Shah K. Stem-cell based therapies for brain tumors. Curr Opin Mol Ther. 2008 Aug;10(4):334-42.
40. Zhao Y, Xie P, Zhu XF, Cai ZY. Neural stem cell transplantation and nerve growth factor promote neurological recovery in rats with ischemic stroke. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jul;28(7):1123-6.